Bio-Techne Corporation (TECH) Financials
PeriodFY2026
Published
Bio-Techne reported $1.22 billion in net sales for FY2026, the fiscal year ended June 30, 2026, down 0.4% from a year earlier and leaving the life science tools maker's top line roughly where it stood in fiscal 2025. Net income was $181.86 million, up 147.8%, and operating income was $251.89 million, up 146.3%, but almost all of that increase came from a depressed prior-year base rather than from operating momentum: fiscal 2025 absorbed an impairment on a business classified as held for sale and a non-recurring arbitration award, and fiscal 2026 booked a recovery on that same business. Diluted earnings per share were $1.16, and in June 2026 Bio-Techne agreed to be acquired by Merck KGaA, Darmstadt, Germany, a transaction that was still pending at the date of the annual report.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $1,215,039,000 | down 0.4% |
| Net income | $181,862,000 | up 147.8% |
| Diluted EPS | $1.16 | up 152.2% |
| Operating income | $251,890,000 | up 146.3% |
| Free cash flow | $263,223,000 | up 2.6% |
Company details
| Name | BIO-TECHNE Corp |
|---|---|
| Ticker | TECH |
| CIK | 0000842023 |
| Exchange | Nasdaq |
| State | Minnesota |
| Incorporation | Minnesota |
| SIC | 2836 |
| Office | Life Sciences |
| Industry | Biological Products, (No Diagnostic Substances) |
| Latest period covered | FY2026, ended 2026-06-30, 10-K, accession 0001104659-26-100322 |
| Fiscal year end | 06/30 (MM/DD) |
| Next expected filing | 10-Q around 2026-11-04 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Bio-Techne FY2026
How much revenue did Bio-Techne report in FY2026?
Bio-Techne reported $1.22 billion in net sales for FY2026, the fiscal year ended June 30, 2026. That is down 0.4% from fiscal 2025 and effectively unchanged, with favorable currency translation offsetting the revenue lost to a divested business.
Why did Bio-Techne's net income rise so much in FY2026?
Bio-Techne's net income was $181.86 million in FY2026, up 147.8% from $73.4 million a year earlier, but the increase is mostly a prior-year base effect rather than growth in the business. Fiscal 2025 carried an impairment on a business classified as held for sale and a non-recurring arbitration award, while fiscal 2026 recorded a recovery on that business, and operating income moved the same way, to $251.89 million from $102.25 million.
What was Bio-Techne's earnings per share in FY2026?
Bio-Techne reported diluted earnings per share of $1.16 for FY2026, the fiscal year ended June 30, 2026, against $0.46 in fiscal 2025. As with net income, the year-over-year gain reflects prior-year charges that did not repeat.
How much cash did Bio-Techne generate in FY2026?
Bio-Techne's free cash flow was $263.22 million in FY2026, the fiscal year ended June 30, 2026, up 2.6% from $256.55 million a year earlier. Cash generation was far steadier than reported earnings across the two years.
Where can I get Bio-Techne Corporation (TECH) financial data in machine-readable form?
Ticker Scout publishes Bio-Techne Corporation's financial statements as JSON at https://tickerscout.ai/tech/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/tech/narrative.md and https://tickerscout.ai/tech/events.md. Bio-Techne Corporation's SEC CIK is 0000842023. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Bio-Techne Corporation (TECH) next file with the SEC?
Bio-Techne Corporation (TECH) is expected to file its next Form 10-Q with the SEC on or around November 4, 2026. That date is a projection rather than a company-announced date: it is derived from Bio-Techne Corporation's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-K for FY2026, the period ended 2026-06-30, SEC accession 0001104659-26-100322.
Related companies
How this page was built
This page was built from Bio-Techne Corporation's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names six such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.